<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581072</url>
  </required_header>
  <id_info>
    <org_study_id>NI-AC104</org_study_id>
    <nct_id>NCT02581072</nct_id>
  </id_info>
  <brief_title>A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204</brief_title>
  <official_title>A Double-blind, Double-dummy, Randomized, 4-period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared With Placebo and Moxifloxacin in Subjects With Acne Vulgaris: A Thorough ECG STudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spaulding Clinical Research LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novan, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects
      of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a
      Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Double-Blind, Double-Dummy, Randomized, 4-Period, Crossover Study to Define the ECG Effects
      of SB204 Using a Clinical and a Supratherapeutic Dose Compared with Placebo and Moxifloxacin
      (a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Define ECG effect of SB204 at therapeutic and supratherapeutic dose concentrations as measured by the difference between time-matched baseline adjusted QTcF interval for the groups recieving SB204 and placebo.</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Categorical analysis of the QTc interval to determine number and percentage of time points and subjects by dose group with absolute QT/QTc &gt; 450, 480, and 500 ms.</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>SB204 4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB204 4% once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB204 8% or 12 %</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB204 8 or 12 % (supratherapeutic) once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacillin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Moxifloxacillin 400 mg orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB204 4%</intervention_name>
    <description>Applied topically once</description>
    <arm_group_label>SB204 4%</arm_group_label>
    <other_name>NVN1000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB204 8% or 12%</intervention_name>
    <description>Applied once topically</description>
    <arm_group_label>SB204 8% or 12 %</arm_group_label>
    <other_name>NVN1000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Applied topically once</description>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe acne

          -  20 inflammatory and 25 non-inflammatory acne lesions

        Exclusion Criteria:

          -  Pregnant, trying to become pregnant, or nursing

          -  Known allergy to any component of the topical SB204 formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce Rico, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novan, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spaulding Clinical Research, LLC</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>November 15, 2018</last_update_submitted>
  <last_update_submitted_qc>November 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

